Logo

Gene Bridges Licenses Recombination Technology to Takeda Pharmaceutical

Oct 07, 2008
NEW YORK (GenomeWeb News) – Gene Bridges said today that Osaka, Japan-based drug developer Takeda Pharmaceutical will use Gene Bridges’ recombination technology under a commercial license agreement through its Japanese distributor, Funakoshi.
 
Gene Bridges’ Red/ET recombination technology is used to generate target vectors or to modify E. coli chromosomes. The Red/ET technology allows for engineering of molecules, BACs, or the E. Coli chromosome.
 
Financial terms of the agreement were not released.

Breaking News
The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.